Promoter choice: Who should drive the CAR in T cells?
Chimeric antigen receptor (CAR) T cell therapy is an effective treatment for B cell malignancies, with emerging potential for the treatment of other hematologic cancers and solid tumors. The strength of the promoter within the CAR cassette will alter CAR-polypeptide levels on the cell surface of the...
Main Authors: | Ali Hosseini Rad S M, Aarati Poudel, Grace Min Yi Tan, Alexander D McLellan |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0232915 |
Similar Items
-
Compact Bidirectional Promoters for Dual-Gene Expression in a Sleeping Beauty Transposon
by: Kevin He, et al.
Published: (2020-12-01) -
Synthesis and novel chemistry of phospha(car)boranes and arsaboranes
by: McLellan, Ross
Published: (2011) -
Who should drive humanitarian responses?
by: Nick Cater
Published: (2005-05-01) -
Implications of SARS-CoV-2 Mutations for Genomic RNA Structure and Host microRNA Targeting
by: Ali Hosseini Rad SM, et al.
Published: (2020-07-01) -
Metabolic and Mitochondrial Functioning in Chimeric Antigen Receptor (CAR)—T Cells
by: Ali Hosseini Rad S. M., et al.
Published: (2021-03-01)